Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2644523

COC(=O)c1ccccc1Oc1cc(Oc2cccnc2)cc2[nH]c(-c3ccccn3)nc12.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBFB Q13951 8/20 0.50
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KMT2A Q03164 2/20 0.39
RUNX1 Q01196 3/20 0.39
TDP1 Q9NUW8 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
AXL P30530 1/20 0.36
PKN1 Q16512 1/20 0.35
PKN2 Q16513 1/20 0.35
GCK P35557 1/20 0.35
DHODH Q02127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2645680 0.91 CBFB (0.49) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2646642 0.86 CBFB (0.48) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2644776 0.82 CBFB (0.57) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2645553 0.80 CBFB (0.55) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2644647 0.80 CBFB (0.52) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2644351 0.80 CBFB (0.52) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2645922 0.78 CBFB (0.52) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2646115 0.78 CBFB (0.47) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2646644 0.77 CBFB (0.47) CBFBALDH1A1TP53CYP3A4CYP2D6
SCHEMBL2645549 0.76 CYP19A1 (0.47) CBFBALDH1A1TP53CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 CBFB 1550/4885ALDH1A1 1188/4885TP53 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.